Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia

详细信息    查看全文

• 作者：Kai-fa Tang (1) (2)
  Yi-li Zhao (1)
  Shang-shu Ding (2)
  Qi-fei Wu (2)
  Xing-yang Wang (2)
  Jia-qi Shi (1)
  Fa Sun (1)
  Jun-ping Xing (2)
  
  1. Department of Urology ; Affiliated Hospital of Guiyang Medical College ; Guiyang ; 550004 ; China
  2. Department of Urology ; the First Affiliated Hospital of Medical College of Xi鈥檃n Jiaotong University ; Xi鈥檃n ; 710061 ; China
  
• 关键词：Infertility ; Cytochrome P450 ; Oligozoospermia ; Tamoxifen ; Testosterone ; R698.2 ; 鐢锋€т笉鑲茬棁 ; 缁嗚優鑹茬礌P450 ; 灏戠簿瀛愮棁 ; 浠栬帿鏄旇姮 ; 鎬ф縺绱?/li>
• 刊名：Journal of Zhejiang University SCIENCE B
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：16
• 期：3
• 页码：191-197
• 全文大小：412 KB
• 参考文献：1. Adamopoulos, DA, Nicopoulou, S, Kapolla, N (1997) The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil. Steril. 67: pp. 756-762 CrossRef
  2. Adamopoulos, DA, Pappa, A, Billa, E (2003) Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil. Steril. 80: pp. 914-920 CrossRef
  3. Borges, S, Desta, Z, Li, L (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80: pp. 61-74 CrossRef
  4. Buvat, J, Ardaens, K, Lemaire, A (1983) Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil. Steril. 39: pp. 700-703
  5. Chua, ME, Escusa, KG, Luna, S (2013) Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a metaanalysis. Andrology 1: pp. 749-757 CrossRef
  6. Comhaire, F (1976) Treatment of oligospermia with tamoxifen. Int. J. Fertil. 21: pp. 232-238
  7. Desta, Z, Ward, BA, Soukhova, NV (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310: pp. 1062-1075 CrossRef
  8. Garcia-Barcelo, M, Chow, LY, Chiu, HF (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 46: pp. 18-23
  9. Ji, L, Pan, SX, Wu, JM (2002) Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J. 115: pp. 1780-1784
  10. Ji, L, Pan, SX, Marti-Jaun, J (2002) Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem. 48: pp. 983-988
  11. Jin, Y, Desta, Z, Stearns, V (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97: pp. 30-39 CrossRef
  12. Johansson, I, Oscarson, M, Yue, QY (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46: pp. 452-459
  13. Kadioglu, TC, Koksal, IT, Tunc, M (1999) Treatment of idiopathic and postvaricocelectomy oligozoospermia with oral tamoxifen citrate. BJU Int. 83: pp. 646-648 CrossRef
  14. Kotoulas, IG, Cardamakis, E, Michopoulos, J (1994) Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fertil. Steril. 61: pp. 911-914
  15. Lin, CH, Lien, HC, Hu, FC (2010) Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.) 11: pp. 1-9 CrossRef
  16. Lu, WJ, Desta, Z, Flockhart, DA (2012) Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res. Treat. 131: pp. 473-481 CrossRef
  17. Rowe, PJ, Comhaire, FH, Hargreave, TB (2000) WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. Cambridge University Press, London, England
  18. Sachse, C, Brockmoller, J, Bauer, S (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60: pp. 284-295
  19. Squirewell, EJ, Qin, X, Duffel, MW (2014) Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab. Dispos. 42: pp. 1843-1850 CrossRef
  20. Stearns, V, Johnson, MD, Rae, JM (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95: pp. 1758-1764 CrossRef
  21. Vermeulen, A, Comhaire, F (1978) Hormonal effects of an antiestrogen, tamoxifen, in normal and oligospermic men. Fertil. Steril. 29: pp. 320-327
  WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interactions. Cambridge University Press, London, England
  22. Xu, Y, Sun, Y, Yao, L (2008) Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19: pp. 1423-1429 CrossRef
  
• 刊物主题：Biomedicine general;
• 出版者：Springer Berlin Heidelberg
• ISSN：1862-1783

文摘

Tamoxifen citrate, as the first line of treatment for infertile men with idiopathic oligozoospermia, was proposed by the World Health Organization (WHO), and testosterone undecanoate has shown benefits in semen values. Our objective was to assess the effectiveness of treatment with tamoxifen citrate and testosterone undecanoate in infertile men with idiopathic oligozoospermia, and whether the results would be affected by polymer-phisms of CYP2D6*10. A total of 230 infertile men and 147 controls were included in the study. Patients were treated with tamoxifen citrate and testosterone undecanoate. Sex hormone, sperm parameters, and incidence of spontaneous pregnancy were detected. There were no significant differences between the control and patient groups with respect to CYP2D6*10 genotype frequencies (P>0.05). The follicle-stimulation hormone (FSH), luteinizing hormone (LH), and testosterone (T) levels were raised, and sperm concentration and motility were increased at 3 months and became significant at 6 months, and they were higher in the wild-type allele (C/C) than in the heterozygous variant allele (C/T) or homozygous variant allele (T/T) subgroups (PPPCYP2D6*10 variant genotype demonstrated worse clinical effects in infertile men with idiopathic oligozoospermia.